A Backstage View Of Roche’s Recent Collaborations
Deal-Making Activities Continue In Full Force Amid Coronavirus Chaos
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
You may also be interested in...
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
One of the decade's largest Series A financings for a biopharmaceutical start-up and a potentially lucrative collaboration with Roche mark the unveiling of C4 Therapeutics, which will work primarily with partners to develop what it calls Degronomids against targeted disease-causing proteins.
Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.